Table 3.
Effect of pre-treatment of rosiglitazone in cisplatin treated rats on % tumour inhibition in chemically induced breast cancer model
| 0 Day | 3rd Day | 6th Day | 9th Day | |
|---|---|---|---|---|
| Normal control | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Breast cancer control | 100 ± 45.22 | 188.26 ± 22.86 | 254.34 ± 19.83 | 282.60 ± 22.46 |
| Rosi (8 mg/kg) | 100 ± 21.24 | 85.84 ± 31.44 | 83.62 ± 38.62**a | 81.85 ± 10.27**a |
| Cis (7.5 mg/kg) | 100 ± 25.56 | 82.95 ± 23.78 | 72.64 ± 25.31**a | 68.60 ± 22.88***a |
| PT Rosi (8 mg/kg) + Cis (7.5 mg/kg) | 100 ± 40.78 | 79.12 ± 34.36*a | 60.67 ± 36.80**a | 54.85 ± 31.86***a |
Percentage tumor inhibition is assessed by calculating the percentage of reduction in tumor volume in the respective treated groups as compared to breast cancer control All values are expressed as mean ± SEM (n = 8). ***P < 0.001, **<0.01, *P < 0.05. a Vs Cancer Control. Where Rosi is rosiglitazone, Cis is cisplatin and PT is pretreatment.